Regeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month High – Here’s What Happened

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) hit a new 52-week high on Wednesday . The company traded as high as $849.93 and last traded at $847.1380, with a volume of 277201 shares. The stock had previously closed at $823.82.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sector outperformance and favorable outlook: Regeneron has outpaced the healthcare sector, while analysts remain moderately optimistic about its prospects. The stock is trading well above its 50-day and 200-day moving averages, indicating strong recent momentum. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Positive Sentiment: Long-term complement-inhibitor opportunity: A new market report projects substantial growth in the global complement-inhibitors market through 2035 and lists Regeneron among the leading participants. This supports the company’s longer-term pipeline and commercial opportunity, though the report does not announce a specific new Regeneron product or financial forecast. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Continued demand for Libtayo: Regeneron is identified as a key player in the expanding non-melanoma skin-cancer treatment market, where Libtayo is an approved therapy. The industry growth outlook is constructive, but the article provides no new sales, approval, or guidance information for Regeneron. Non-Melanoma Skin Cancer Market Report
• Negative Sentiment: Multiple securities lawsuits increase risk: Several law firms announced or promoted class actions against Regeneron on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The complaints allege that Regeneron and executives misrepresented risks surrounding the Phase III fianlimab-Libtayo melanoma trial, including slowing event accrual, clinical differentiation, and a late protocol amendment. The allegations have not been proven, but the litigation could increase legal costs, reputational risk, and uncertainty around the drug’s growth prospects. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Class Action Announcement

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent analyst reports. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Canaccord Genuity Group cut their price target on shares of Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Fourteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $800.36.

Regeneron Pharmaceuticals Stock Up 3.2%

The firm has a market capitalization of $87.53 billion, a PE ratio of 20.99, a price-to-earnings-growth ratio of 1.36 and a beta of 0.19. The firm’s 50-day moving average is $725.36 and its 200 day moving average is $718.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm posted $12.81 EPS. As a group, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $482,400. The trade was a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,400 shares of company stock valued at $1,090,030. 6.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in REGN. Insigneo Advisory Services LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.0% during the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after purchasing an additional 13 shares during the last quarter. Arjuna Capital boosted its position in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock worth $353,000 after acquiring an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC boosted its position in Regeneron Pharmaceuticals by 3.3% during the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 14 shares during the last quarter. TD Private Client Wealth LLC grew its stake in Regeneron Pharmaceuticals by 9.7% in the 4th quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 15 shares during the period. Finally, MCF Advisors LLC grew its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 15 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.